| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
|
Pfisterer, Jacobus
|
|
|
21 |
5 |
p. 699-709
|
artikel
|
| 2 |
Cancer care for refugees: time to invest in people and systems
|
Ilbawi, André
|
|
|
21 |
5 |
p. 604-605
|
artikel
|
| 3 |
Cancer care in the time of COVID-19
|
Burki, Talha Khan
|
|
|
21 |
5 |
p. 628
|
artikel
|
| 4 |
Cancer guidelines during the COVID-19 pandemic
|
Burki, Talha Khan
|
|
|
21 |
5 |
p. 629-630
|
artikel
|
| 5 |
Cancer in Syrian refugees in Jordan and Lebanon between 2015 and 2017
|
Spiegel, Paul B
|
|
|
21 |
5 |
p. e280-e291
|
artikel
|
| 6 |
CAR T-cell therapy for relapsed or refractory mantle-cell lymphoma
|
Stirrups, Robert
|
|
|
21 |
5 |
p. e239
|
artikel
|
| 7 |
Challenges posed by COVID-19 to children with cancer
|
Kotecha, Rishi S
|
|
|
21 |
5 |
p. e235
|
artikel
|
| 8 |
Clinical implications of food–drug interactions with small-molecule kinase inhibitors
|
Veerman, G D Marijn
|
|
|
21 |
5 |
p. e265-e279
|
artikel
|
| 9 |
COVID-19: impact on cancer workforce and delivery of care
|
Mayor, Susan
|
|
|
21 |
5 |
p. 633
|
artikel
|
| 10 |
Cutaneous metastasis of renal cell carcinoma
|
Lee, Han Jie
|
|
|
21 |
5 |
p. e292
|
artikel
|
| 11 |
Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial
|
Tomao, Federica
|
|
|
21 |
5 |
p. 616-617
|
artikel
|
| 12 |
FGFR inhibitors for advanced cholangiocarcinoma
|
Yang, Tian
|
|
|
21 |
5 |
p. 610-612
|
artikel
|
| 13 |
Fulvestrant plus capivasertib for metastatic breast cancer
|
Dekker, Tim Johannes Adrianus
|
|
|
21 |
5 |
p. e232
|
artikel
|
| 14 |
Fulvestrant plus capivasertib for metastatic breast cancer
|
Ludmir, Ethan B
|
|
|
21 |
5 |
p. e233
|
artikel
|
| 15 |
Fulvestrant plus capivasertib for metastatic breast cancer – Authors' reply
|
Jones, Robert H
|
|
|
21 |
5 |
p. e234
|
artikel
|
| 16 |
Glioma patient-reported outcome assessment in clinical care
|
Tuleasca, Constantin
|
|
|
21 |
5 |
p. e230
|
artikel
|
| 17 |
Glioma patient-reported outcome assessment in clinical care – Authors' reply
|
Armstrong, Terri S
|
|
|
21 |
5 |
p. e231
|
artikel
|
| 18 |
Hepatic metastases resection after cetuximab: are we missing something?
|
Ulusakarya, Ayhan
|
|
|
21 |
5 |
p. e228
|
artikel
|
| 19 |
Hepatic metastases resection after cetuximab: are we missing something? – Authors' reply
|
Pugh, Sian A
|
|
|
21 |
5 |
p. e229
|
artikel
|
| 20 |
Lack of protective gear disrupts oncology care
|
Nelson, Roxanne
|
|
|
21 |
5 |
p. 631-632
|
artikel
|
| 21 |
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
|
Trigo, José
|
|
|
21 |
5 |
p. 645-654
|
artikel
|
| 22 |
Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan
|
Mei, Heng
|
|
|
21 |
5 |
p. 634-636
|
artikel
|
| 23 |
New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer
|
Arrieta, Oscar
|
|
|
21 |
5 |
p. 605-607
|
artikel
|
| 24 |
New therapy for children with plexiform neurofibromas
|
Gourd, Elizabeth
|
|
|
21 |
5 |
p. e238
|
artikel
|
| 25 |
Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors
|
Barlesi, Fabrice
|
|
|
21 |
5 |
p. 607-608
|
artikel
|
| 26 |
Outcome measures in multimodal rectal cancer trials
|
Fokas, Emmanouil
|
|
|
21 |
5 |
p. e252-e264
|
artikel
|
| 27 |
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
|
Goldberg, Sarah B
|
|
|
21 |
5 |
p. 655-663
|
artikel
|
| 28 |
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
|
Abou-Alfa, Ghassan K
|
|
|
21 |
5 |
p. 671-684
|
artikel
|
| 29 |
Platinum-sensitive ovarian cancer: liminal advances
|
Penson, Richard T
|
|
|
21 |
5 |
p. 614-615
|
artikel
|
| 30 |
Preparedness for COVID-19 in the oncology community in Africa
|
Vanderpuye, Verna
|
|
|
21 |
5 |
p. 621-622
|
artikel
|
| 31 |
Preparing African anticancer centres in the COVID-19 outbreak
|
Souadka, Amine
|
|
|
21 |
5 |
p. e237
|
artikel
|
| 32 |
Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis
|
Vokinger, Kerstin N
|
|
|
21 |
5 |
p. 664-670
|
artikel
|
| 33 |
Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study
|
Koller, Michael
|
|
|
21 |
5 |
p. 723-732
|
artikel
|
| 34 |
Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ
|
Benson, John R
|
|
|
21 |
5 |
p. 612-614
|
artikel
|
| 35 |
Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial
|
King, Madeleine T
|
|
|
21 |
5 |
p. 685-698
|
artikel
|
| 36 |
Quality of life in patients with lung cancer: the way forward
|
Reale, Maria Lucia
|
|
|
21 |
5 |
p. 617-619
|
artikel
|
| 37 |
Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic
|
de Paula, Bruno H R
|
|
|
21 |
5 |
p. 624-627
|
artikel
|
| 38 |
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
|
Ledermann, Jonathan A
|
|
|
21 |
5 |
p. 710-722
|
artikel
|
| 39 |
Safeguarding cancer care in a post-COVID-19 world
|
The Lancet Oncology,
|
|
|
21 |
5 |
p. 603
|
artikel
|
| 40 |
Taking care of older patients with cancer in the context of COVID-19 pandemic
|
Mourey, Loïc
|
|
|
21 |
5 |
p. e236
|
artikel
|
| 41 |
TAS-102 plus bevacizumab in metastatic colorectal cancer
|
Colloca, Giuseppe A
|
|
|
21 |
5 |
p. e226
|
artikel
|
| 42 |
TAS-102 plus bevacizumab in metastatic colorectal cancer – Authors' reply
|
Pfeiffer, Per
|
|
|
21 |
5 |
p. e227
|
artikel
|
| 43 |
The economic burden of cancer care for Syrian refugees: a population-based modelling study
|
Abdul-Khalek, Rima A
|
|
|
21 |
5 |
p. 637-644
|
artikel
|
| 44 |
The global imperative to make cancer medications affordable
|
Cherny, Nathan I
|
|
|
21 |
5 |
p. 609-610
|
artikel
|
| 45 |
The increasing value of eHealth in the delivery of patient-centred cancer care
|
Penedo, Frank J
|
|
|
21 |
5 |
p. e240-e251
|
artikel
|
| 46 |
The official French guidelines to protect patients with cancer against SARS-CoV-2 infection
|
You, Benoit
|
|
|
21 |
5 |
p. 619-621
|
artikel
|
| 47 |
The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19
|
|
|
|
21 |
5 |
p. 622-624
|
artikel
|
Tijdschrift beschrijving